25 jun: North Media A/S opjusterer forventningerne til 2019
26 jun: DSV, 759 - DSV forlænger ombytningsperiode for Panalpina aktier
25-06-2019 18:42:01

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement

Copenhagen, Denmark; June 25, 2019 –

Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 9,577 shares as a consequence of the exercise of employee warrants.

The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:

230 shares at DKK 40.41,

500 shares at DKK 66.60,

750 shares at DKK 79.25,

1,625 shares at DKK 80.55,

250 shares at DKK 129.75,

275 shares at DKK 220.40,

750 shares at DKK 225.90,

225 shares at DKK 231.50,

2,125 shares at DKK 337.40,

100 shares at DKK 466.20,

1,425 shares at DKK 623.50,

500 shares at DKK 636.50,

147 shares at DKK 1,145.00, and

675 shares at DKK 1,233.00.

Proceeds to the company are approximately DKK 3.52 million. The increase corresponds to approx. 0.016 % of the company's share capital.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription, i.e. inter alia full rights to dividends for the financial year 2019. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. The capital increase is expected to be finalized shortly.

Pursuant to section 32 of the Danish Capital Markets Act No 459 of April 24, 2019, it is hereby announced, that the total nominal value of Genmab A/S' share capital after the capital increase is DKK 61,690,143, which is made up of 61,690,143 shares of a nominal value of DKK 1 each, corresponding to 61,690,143 votes.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers and amyloidosis. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies and the HexElect® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.

Contact:          

Marisol Peron, Corporate Vice President, Communications & Investor Relations

T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations:

Andrew Carlsen, Senior Director, Investor Relations

T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody®; HexElect®; and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Pharmaceutica NV.

 

 

Company Announcement no. 28

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

Attachment

logo.jpg

Relateret indhold
17 jul - 
Onsdagens aktier: Danske Bank og Nordea faldt forud for..
17 jul - 
Aktier/middag: Danske og Nordea falder efter nordiske b..
16 jul - 
Tirsdagens aktier: Genmab steg til vejrs efter Darzalex..
Relateret debat
17 jul - 
Hvornår forventes det at Genmab bliver noteret i USA? H..
17 jul - 
Ligner en klassiker ... https://invst.ly/baf-3 :-))
17 jul - 
Det er min tanke, men TA/og jeg, er ikke fejlfri ! Dygt..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
16 jul
GEN
Med markering:   https://ir.genmab.com/news-releases/news-release-details/genmab-announces-net-sales..
7
12 jul
GEN
Til information var jeg til orienteringsmøde hos Danske bank igår omkring Genmab m.fl.Der er nyt kur..
7
16 jul
GEN
Evt godkendelse forventes ultimo 2019 og på markedet  Q1 20 SC-behandlingen bliver sandsynligvis væs..
5
16 jul
GEN
Markedsværdi ca. 75 mia for hele butikken svarer vel stort set til den pris som Celgene for ca. 2 år..
5
12 jul
GEN
Og de eksisterende aktionærer bliver igen tørret i ræven? ingen udbytte, ingen fortegningsret, ingen..
5
16 jul
GEN
Nogle analytikere påpeger at trækker man valuta og engangs pillerier ud, så er det som forventet, do..
4
12 jul
GEN
Tirsdag, så har vi tallene fra J&J.   Denne gang får vi for alvor de europæiske salgstal ind i bille..
4
16 jul
GEN
"en grådig ledelse som man tænker vil gøre alt for at øge kursen"   Den er jeg med på. 
3
16 jul
GEN
Ang. analytiker kommentarer. Jeg er kunde i Nordea og har derfor mulighed for at læse Novrods Genmab..
3
16 jul
GEN
vækst:   1. ste kvartal fra 2018 til 2019:   46 %   2. en kvartal fra 2019 til 2019:   51 %   Vækste..
3

Aktier/tendens: Knaphed på positivt nyt før åbning med spot på banker

17-07-2019 08:24:44
Bortset fra en marginalt stigende future for det amerikanske S&P 500-indeks er der ikke meget, der peger i positiv retning for det danske aktiemarkedet op til åbningen onsdag morgen.I USA lukkede markederne med fald i alle tre toneangivende indeks, som dermed ikke kunne fortsætte rekordrækken. Og fra Asien kan en trykket stemning give negativ inspiration til den europæiske handel.Tirsdag lukkede d..

Goldman Sachs: Højere indtægter kravlede ikke med på bunden

16-07-2019 13:51:32
Indtægterne fra aktiehandel, som er et vigtigt område for den amerikanske storbank Goldman Sachs, klarede sig bedre end analytikerne havde ventet i andet kvartal. Men selv om de samlede indtægter også steg en smule, bevægede de sig ikke med ned på bundlinjen i regnskabet for kvartalet.Det skriver Bloomberg News.På bundlinjen præsenterede den New York-baserede bank et overskud på 5,81 dollar per ak..

Aktier/tendens: Stilstand på sommertynde markeder - Genmab i fokus

16-07-2019 08:06:06
Genmab kan komme i fokus tirsdag, når det amerikanske medicinalselskab Johnson & Johnson over middag kommer med regnskab for andet kvartal af 2019, da det fortæller, hvordan det globale salg af kræftmidlet Darzalex arter sig.Samlet peger det på en forholdsvis neutral åbning på det danske aktiemarked, hvis retningen skal tages efter futures for det tyske DAX-indeks, der ligger til et svagt plus.Man..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Danske Bank/Credit Suisse: Sænker kursmål før regnskabsdag
2
Fonde tjener over en milliard kroner på Ambus nedtur
3
Aktier/åbning: Tæt på statisk med Vestas og Danske Bank i yderpunkter
4
Onsdagens aktier: Danske Bank og Nordea faldt forud for regnskaber
5
Aktier/tendens: Knaphed på positivt nyt før åbning med spot på banker

Relaterede aktiekurser

Genmab A/S 1,216.00 -0,3% Fald i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
18. juli 2019 06:39:02
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190703.1 - EUROWEB3 - 2019-07-18 06:39:02 - 2019-07-18 06:39:02 - 1 - Website: OKAY